The Norwegian "New Method" framework is developing prioritization criteria for the evaluation of medical technologies and procedures

02

Feb 2022

In 2013, Norway established a framework, "New Method," for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. In this framework, all innovations should undergo HTA before being funded. The "New Method" is currently developing criteria for which methods other than drugs shall be prioritized for assessment within the framework at the national or local levels.

 The "New method" framework evaluates three types of methods:

  • Drugs
  • Medical equipment, diagnostics, and tests
  • Procedures and organizational measures

For now, there are no clear criteria for methods other than drugs, and it is partly random which technology will be evaluated within the "New Method" framework.

In January 2021, the Ordering Forum of "New Method" commissioned the project to develop criteria for which methods other than drugs shall be prioritized for assessment within the framework at the national or local levels. Two groups were created to work on the project. The main group consists of the National Institute of Public Health (NIPH), the regional health authorities (RHA), Hospital Procurement HF, Melanor (industry association), Secretariat of the "New Method" and others; the internal group consists of NIPH, Hospital Procurement HF, and Secretariat. Every group had two meetings in 2021.

On January 17, 2022, the project status was presented at the Ordering Forum for "New Method." It was reported that the project would require more resources and time than initially thought. The assignment concerned "methods other than drugs," but initially, only medical technology (equipment, diagnostics, and tests) was considered. The internal group now suggests assessing whether the same set of criteria can be used for procedures and organizational measures. Secretariate also asked Ordering Forum to clarify whether criteria for artificial intelligence and digital technologies should also be considered.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more